-
2
-
-
0027500750
-
Treatment of Parkinson's disease
-
Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993; 329:1021-27.
-
(1993)
N Engl J Med
, vol.329
, pp. 1021-1027
-
-
Calne, D.B.1
-
3
-
-
0001905621
-
Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease
-
Koller W, editor. New York: Marcel Dekker Inc
-
Jankovic J. Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease. In: Koller W, editor. Handbook of Parkinson's disease. New York: Marcel Dekker Inc; 2003. p.99-126.
-
(2003)
Handbook of Parkinson's Disease
, pp. 99-126
-
-
Jankovic, J.1
-
5
-
-
0037072288
-
Nonmotor fluctuations in Parkinson's disease: Frequent and disabling
-
Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-13.
-
(2002)
Neurology
, vol.59
, pp. 408-413
-
-
Witjas, T.1
Kaphan, E.2
Azulay, J.P.3
Blin, O.4
Ceccaldi, M.5
Pouget, J.6
-
6
-
-
0037769604
-
Cognitive and behavioral disturbances in Parkinson's disease
-
Girotti F, Soliveri P. Cognitive and behavioral disturbances in Parkinson's disease. Neurol Sci 2003;24 Suppl 1:S30-1.
-
(2003)
Neurol Sci
, vol.24
, Issue.1 SUPPL.
-
-
Girotti, F.1
Soliveri, P.2
-
7
-
-
0034642340
-
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors
-
Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000; 55 Suppl 4:S72-77.
-
(2000)
Neurology
, vol.55
, Issue.4 SUPPL.
-
-
Olanow, C.W.1
Obeso, J.A.2
-
8
-
-
0034684139
-
Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
-
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial. JAMA 2000;284:1931-8.
-
(2000)
JAMA
, vol.284
, pp. 1931-1938
-
-
-
9
-
-
18744437329
-
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approach
-
Merims D, Ziv I, Sherki Y, Djaldetti R, Melamed E. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approach. Neurol Neurochir Pol 2001;35 Suppl 3:65-8.
-
(2001)
Neurol Neurochir Pol
, vol.35
, Issue.3 SUPPL.
, pp. 65-68
-
-
Merims, D.1
Ziv, I.2
Sherki, Y.3
Djaldetti, R.4
Melamed, E.5
-
10
-
-
0033971510
-
Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what
-
Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 2000;15:3-8.
-
(2000)
Mov Disord
, vol.15
, pp. 3-8
-
-
Metman, L.V.1
Konitsiotis, S.2
Chase, T.N.3
-
11
-
-
0034932441
-
Amantadine for dyskinesia in patients affected by severe Parkinson's disease
-
Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 2001;22:75-6.
-
(2001)
Neurol Sci
, vol.22
, pp. 75-76
-
-
Paci, C.1
Thomas, A.2
Onofrj, M.3
-
13
-
-
0032983786
-
Memantine in severe dementia: Results of the 9M-Best Study. Benefit and efficacy in severely demented patients during treatment with memantine
-
Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study. Benefit and efficacy in severely demented patients during treatment with memantine. Int J Geriatr Psychiatry 1999; 14:135-46.
-
(1999)
Int J Geriatr Psychiatry
, vol.14
, pp. 135-146
-
-
Winblad, B.1
Poritis, N.2
-
14
-
-
0037417238
-
Memantine in moderate to severe Alzheimer's disease
-
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate to severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
-
(2003)
N Engl J Med
, vol.348
, pp. 1333-1341
-
-
Reisberg, B.1
Doody, R.2
Stoffler, A.3
Schmitt, F.4
Ferris, S.5
Mobius, H.J.6
-
15
-
-
0026701318
-
Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
-
Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm 1992;4:277-82.
-
(1992)
J Neural Transm
, vol.4
, pp. 277-282
-
-
Rabey, J.M.1
Nissipeanu, P.2
Korczyn, A.D.3
-
16
-
-
0032730121
-
Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study
-
Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study. Clin Neuropharmacol 1999; 22(3):273-6.
-
(1999)
Clin Neuropharmacol
, vol.22
, Issue.3
, pp. 273-276
-
-
Merello, M.1
Nouzeilles, M.I.2
Cammarota, A.3
Leiguarda, R.4
-
17
-
-
0035353725
-
Frequency of levodopa-related dyskinesia and motor fluctuations as estimated from the literature
-
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesia and motor fluctuations as estimated from the literature. Mov Disord 2001;16:448-58.
-
(2001)
Mov Disord
, vol.16
, pp. 448-458
-
-
Ahlskog, J.E.1
Muenter, M.D.2
-
18
-
-
0032554497
-
Adverse reactions to levodopa: Drug toxicity or progression of the disease?
-
Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of the disease? Lancet 1998;351:851-2.
-
(1998)
Lancet
, vol.351
, pp. 851-852
-
-
Agid, Y.1
Chase, T.2
Marsden, D.3
-
19
-
-
0031976069
-
The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease
-
Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55 Suppl 1:1-9.
-
(1998)
Drugs
, vol.55
, Issue.1 SUPPL.
, pp. 1-9
-
-
Chase, T.N.1
-
21
-
-
17344374331
-
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa
-
Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs 1998;55 Suppl 1:17-22.
-
(1998)
Drugs
, vol.55
, Issue.1 SUPPL.
, pp. 17-22
-
-
Marsden, C.D.1
|